Hannah Maria Miles, Author at Fragile X Research

Ganaxolone Fragile X Clinical Trial Showed Disappointing Results

Hannah Maria Miles Dijck, Anke Van • Kooy, Frank • Research Updates • University of Antwerp, Belgium February 7, 2019February 12, 2019amyloid precursor protein, GABA, ganaxolone, mGluR, NIH, seizure, sleep, TAT (Trans-Activator of Transcription)

Ganaxolone, an experimental drug from Marinus Pharmaceuticals which targets GABA receptors, did not show promise for Fragile X syndrome in a clinical trial.

Mega Green Tea Extract to Treat Fragile X?

Hannah Maria Miles de la Torre, Rafael • Dierssen, Mara • Research Updates August 22, 2018February 12, 2019Alzheimer's, amyloid precursor protein, estrogen, NIH

Green tea is thought to have many benefits, particularly in cognitive function. In 2012-14, FRAXA Research Foundation funded a clinical trial to assess the effects of EGCG (green tea extract) on cognitive function in adults with FXS. Drs. Rafael de la Torre and Mara Dierssen Sotos, principal researchers in Barcelona, Spain, reported memory, attention, and mental flexibility improvements.

Aripiprazole as a Treatment for Fragile X Syndrome

Hannah Maria Miles Clinical Trials • Erickson, Craig • Research Grant Results • Research Updates June 28, 2018June 29, 2018Abilify, amyloid precursor protein, aripiprazole, autism, iPS, NIH

Many medications are used to help people with Fragile X cope. But few clinical trials have been done on these drugs. Years ago FRAXA funded Dr. Craig Erickson to run a trial of aripiprazole (aka Abilify). FRAXA guest writer Hannah Miles recently caught up with Dr. Erickson to learn the results of the trial.